Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 10/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9962063 | 0.95 | MAPT (0.46) | TP53MAPTSMN1; SMN2KIF11SIRT1 | |
| SCHEMBL9962088 | 0.95 | MAPT (0.46) | TP53MAPTSMN1; SMN2KIF11SIRT1 | |
| SCHEMBL8403146 | 0.92 | TP53 (0.47) | TP53MAPTSMN1; SMN2KIF11SIRT1 | |
| SCHEMBL9962090 | 0.91 | TP53 (0.43) | TP53MAPTSMN1; SMN2KIF11SIRT1 | |
| SCHEMBL9962093 | 0.90 | TP53 (0.47) | TP53MAPTSMN1; SMN2KIF11SIRT1 | |
| SCHEMBL8404211 | 0.90 | TP53 (0.49) | TP53MAPTSMN1; SMN2KIF11SIRT1 | |
| SCHEMBL8404210 | 0.90 | TP53 (0.48) | TP53MAPTSMN1; SMN2KIF11SIRT1 | |
| SCHEMBL764664 | 0.89 | TP53 (0.48) | TP53MAPTSMN1; SMN2KIF11SIRT1 | |
| SCHEMBL12979318 | 0.89 | TP53 (0.45) | TP53MAPTSMN1; SMN2KIF11SIRT1 | |
| SCHEMBL8403136 | 0.88 | TP53 (0.49) | TP53MAPTSMN1; SMN2KIF11SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178707-A1 | METHODS FOR TREATING PROSTRATE CONDITIONS | PTC THERAPEUTICS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-20120178707-A1 | METHODS FOR TREATING PROSTRATE CONDITIONS | PTC THERAPEUTICS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-20120157400-A1 | METHODS FOR TREATING KAPOSI SARCOMA | PTC THERAPEUTICS, INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120157402-A1 | METHODS FOR TREATING BRAIN TUMORS | PTC THERAPEUTICS, INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120157402-A1 | METHODS FOR TREATING BRAIN TUMORS | PTC THERAPEUTICS, INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120157400-A1 | METHODS FOR TREATING KAPOSI SARCOMA | PTC THERAPEUTICS, INC. | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157402-A1 | METHODS FOR TREATING BRAIN TUMORS | HDGF, VEGFA, FLT4 | TP53 61/4885MAPT 1046/4885SMN1; SMN2 2143/4885 |
| US-20120157400-A1 | METHODS FOR TREATING KAPOSI SARCOMA | HDGF, HIF1AN, VEGFA | TP53 17/4885MAPT 3684/4885SMN1; SMN2 2479/4885 |
| US-20120178707-A1 | METHODS FOR TREATING PROSTRATE CONDITIONS | ACP3, BPHL, PTGFR | TP53 380/4885MAPT 1384/4885SMN1; SMN2 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.